Lyme disease is a bacterial infection transmitted to humans by blacklegged ticks. It is the most common tick-borne disease in the Northern Hemisphere, with 20,000 cases reported annually. Named after the Connecticut town where a cluster was reported in 1977, Lyme disease was first described in the 1880s. Public health authorities and most clinical experts eschew the term chronic Lyme disease (CLD). Post-Lyme disease syndrome (PLDS) is the preferred term for previously infected patients whose symptoms persist or progress.
Causes of Lyme Disease
The anaerobic spirochete Borrelia burgdorferi causes Lyme disease. Early symptoms include rash, fever, chills, fatigue, and aches. In time the disease may affect the joints, heart, brain, and central nervous system, producing a baffling variety of symptoms sometimes mistaken for other diseases, such as viral infections, joint disorders, fibromyalgia and other pain disorders, chronic fatigue syndrome, and depression. Other bacterial infections introduced by the offending tick can make diagnosis and treatment even more difficult.
Treatment of Lyme Disease with Hyperbaric Oxygen Therapy
Clinicians prescribe hyperbaric oxygen therapy for Lyme disease as an adjunct to antibiotics. As in the treatment of
HBOT may inhibit the growth of anaerobic bacteria by improving blood flow and oxygenating infected tissue. Some practitioners also claim that hyperbaric oxygen may help manage associated pain and depression, improve mental clarity, and reduce or eliminate the long-term use of antibiotics. Evidence in the medical literature does not yet support these claims.
HyperbaricLink Evidence Index for Lyme Disease
The HyperbaricLink Evidence Index is our at-a-glance summary of the clinical evidence on HBOT for the treatment of specific diseases and conditions. Scoring is based solely on our reading and interpretation of the medical literature.
- Disproved - Strong evidence against using HBOT.
- None - Unfavorable results or no published evidence.
- Scant - Early or mixed results with lingering questions.
- Promising - Repeatedly favorable results urging further study.
- Compelling - Strong body of evidence meriting approval.
- Approved - HBOT indicated and widely reimbursed.
Follow the links to our primary sources to read the papers and analyses that have shaped our views. PubMed.gov lists most all scientific papers published in reputable medical journals. HBOEvidence.com critically appraises key studies in the hyperbaric medical literature. ClinicalTrials.gov lists human clinical trials currently enrolling, in progress, and recently completed.
More information on Lyme Disease
NOT APPROVED indication for HBOT by UHMS
HBOT news about Lyme Disease
Multibillion-dollar Losses at JPMorgan Linked to Key Executive's Struggle with Lyme Disease
When we read "JPMorgan's $6 Billion Case of Lyme Disease" in Forbes we thought maybe it was an Onion headline. But, sure enough, bank insiders and Wall Street traders have placed part of the blame for the massive blunder on the
More news from O2.0 – the HyperbaricLink blog
Complete Lyme disease news archive from O2.0 — the HyperbaricLink blog.